Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

NCT03382418 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: gp145 C.6980 Vaccine
BIOLOGICAL: Placebo
BIOLOGICAL: Aluminum Hydroxide Adjuvant

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)